GIVLAARI (givosiran sodium)
AHP AGENTS - ALAS1 MRNA DEGRADATION · ACUTE HEPATIC PORPHYRIA
ALNYLAM PHARMAC
Drug class
AHP Agents - ALAS1 mRNA Degradation
The therapeutic drug class "AHP Agents - ALAS1 mRNA Degradation" is a targeted pharmacotherapeutic category, established in standard drug compendia and represented by small interfering RNA therapeutics such as givosiran. Read more about AHP Agents - ALAS1 mRNA Degradation
1 drugs in this class 1 manufacturers
Drugs in AHP Agents - ALAS1 mRNA Degradation
Filter & compare in the drug finder →
Opens the drug finder with AHP Agents - ALAS1 mRNA Degradation preselected. Add indication or manufacturer filters there.
The therapeutic drug class "AHP Agents - ALAS1 mRNA Degradation" is a targeted pharmacotherapeutic category, established in standard drug compendia and represented by small interfering RNA therapeutics such as givosiran.
These agents utilize RNA interference to direct the catalytic degradation of aminolevulinate synthase 1 messenger RNA specifically within hepatocytes.
By downregulating this rate-limiting enzyme in heme biosynthesis, they markedly suppress the accumulation of neurotoxic heme intermediates, notably delta-aminolevulinic acid and porphobilinogen.
Consequently, this class is indicated for the treatment and prevention of acute neurovisceral attacks and chronic manifestations in adults with acute hepatic porphyria.
-
ashpublications.org
The therapeutic drug class "AHP Agents - ALAS1 mRNA Degradation" is a targeted pharmacotherapeutic category, established in standard drug compendia and represented by small interfering RNA therapeutics such as givosiran These agents utilize RNA interference to direct the catalytic degradation of aminolevulinate synthase 1 messenger RNA specifically within hepatocytes By downregulating this rate-limiting enzyme in heme biosynthesis, they markedly suppress the accumulation of neurotoxic heme inter...
-
ajmc.com
The therapeutic drug class "AHP Agents - ALAS1 mRNA Degradation" is a targeted pharmacotherapeutic category, established in standard drug compendia and represented by small interfering RNA therapeutics such as givosiran
-
tandfonline.com
These agents utilize RNA interference to direct the catalytic degradation of aminolevulinate synthase 1 messenger RNA specifically within hepatocytes
-
porphyriafoundation.org
By downregulating this rate-limiting enzyme in heme biosynthesis, they markedly suppress the accumulation of neurotoxic heme intermediates, notably delta-aminolevulinic acid and porphobilinogen Consequently, this class is indicated for the treatment and prevention of acute neurovisceral attacks and chronic manifestations in adults with acute hepatic porphyria
-
globalgenes.org
Consequently, this class is indicated for the treatment and prevention of acute neurovisceral attacks and chronic manifestations in adults with acute hepatic porphyria
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.